The Expression of ARMCX1 in Gastric Cancer Contributes to Prognosis and Influences Chemotherapy-Reference-Cited by-同舟云学术

The Expression of ARMCX1 in Gastric Cancer Contributes to Prognosis and Influences Chemotherapy

Published:2023-01-23 Issue: Volume:2023 Page:1-12
ISSN:2314-7156
Container-title:Journal of Immunology Research
language:en
Short-container-title:Journal of Immunology Research

Author:

Lv Changheng¹²^ORCID,Yang Di¹²,Zhang Donghu²^ORCID,Shen Jiajia¹,Wang Zechen¹^ORCID,He Siyuan¹,Meng Lingzhang¹³^ORCID,Song Jian¹³^ORCID,Zhao Jingjie⁴^ORCID

Affiliation:

1. Center for Systemic Inflammation Research (CSIR), School of Preclinical Medicine, Youjiang Medical University for Nationalities, Baise, Guangxi Province, China

2. Department of Pediatric Surgery, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi Province, China

3. Institute of Cardiovascular Sciences, Guangxi Academy of Medical Sciences, Nanning, Guangxi Province, China

4. Life Science and Clinical Research Center, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi Province, China

Abstract

The altered expression of ARMCX1 in patients with gastric cancer has been reported frequently, yet its correlation to prognosis and chemotherapy needs to be unveiled. In combination of the gene expression data retrieved from TCGA database and bioinformatic analysis, this study discovered 590 differentially expressed genes in the cancerous biopsies isolated from gastric patients, compared with controls. Among which, ARMCX1 exhibited great potential to serve as a prognostic biomarker for gastric patients; furthermore, patients with low expression of ARMCX1 could be more sensitive to these 9 chemotherapeutic agents: A-770041, AMG-706, ATRA, BEZ235, bortezomib, CGP60474, dasatinib, HG-64-1, and pazopanib, rather than the other chemotherapeutic agents. This study helps the improvement of evaluating the prognosis of gastric cancer patients, and would help optimize chemotherapeutic strategies in consideration of the expression of ARMCX1.

Funder

Youjiang Medical University for Nationalities Research Project

Publisher

Hindawi Limited

Subject

Immunology,General Medicine,Immunology and Allergy

Link

http://downloads.hindawi.com/journals/jir/2023/2623317.pdf

Reference53 articles.

1. Cancer burden in the year 2000. The global picture;D. M. Parkin;European Journal of Cancer,2001

2. International variation

3. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

4. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

5. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries